DARE - セルリアン・ファ―マ (Dare Bioscience Inc.)

DAREのニュース

   Earnings Scheduled For May 11, 2023  2023/05/11 13:58:54 Benzinga
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE: TAK ) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ: XELA ) is expected to report earnings for its first quarter. • Addex Therapeutics (NASDAQ: ADXN ) is projected to report earnings for its first quarter. • Fiverr Intl (NYSE: FVRR ) is expected to report quarterly earnings at $0.24 per share on revenue of $87.66 million. • Teekay (NYSE: TK ) is likely to report earnings for its first quarter. • Teekay Tankers (NYSE: TNK ) is likely to report quarterly earnings at $4.38 per share on revenue of $243.55 million. • Pharming (NASDAQ: PHAR ) is likely to report earnings for its first quarter. • Algonquin Power (NYSE: AQN ) is expected to report quarterly earnings at $0.23 per share on revenue of $983.76 million. • Docebo (NASDAQ: DCBO ) is projected to report quarterly earnings at $0.02 per share on revenue of $55.42 million. • Pioneer Muni High Inc (NYSE: MAV ) is estimated to report quarterly loss at $0.
   Ryuichi Sakamoto: Japanese electronic music maestro dies  2023/04/02 15:05:29 Kwhen Finance
   Earnings Scheduled For March 30, 2023  2023/03/30 11:24:25 Benzinga
Companies Reporting Before The Bell • Creative Realities (NASDAQ: CREX ) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million. • EVgo (NASDAQ: EVGO ) is likely to report quarterly loss at $0.16 per share on revenue of $21.82 million. • Edap TMS (NASDAQ: EDAP ) is likely to report quarterly loss at $0.01 per share on revenue of $17.04 million. • Marketwise (NASDAQ: MKTW ) is estimated to report quarterly earnings at $0.02 per share on revenue of $114.83 million. • Manchester United (NYSE: MANU ) is projected to report quarterly loss at $0.01 per share on revenue of $172.27 million. • Neogen (NASDAQ: NEOG ) is projected to report quarterly loss at $0.01 per share on revenue of $218.86 million. • Cazoo Gr (NYSE: CZOO ) is likely to report earnings for its fourth quarter. • Avadel Pharmaceuticals (NASDAQ: AVDL ) is likely to report earnings for its fourth quarter. • Altisource Portfolio (NASDAQ: ASPS ) is projected to report quarterly loss at $0.65 per share on revenue of $33.
   Infatuating stocks: CytomX Therapeutics, Inc. (NASDAQ:CTMX -0.44%), Dare Bioscience, Inc. (NASDAQ:DARE -0.93%)  2023/02/23 15:17:20 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Infatuating stocks: CytomX Therapeutics, Inc. (NASDAQ:CTMX -0.44%), Dare Bioscience, Inc. (NASDAQ:DARE -0.93%) appeared first on Stocks Equity .
   Holding stocks: CytomX Therapeutics, Inc. (NASDAQ:CTMX), Dare Bioscience, Inc. (NASDAQ:DARE)  2023/02/20 13:08:47 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Holding stocks: CytomX Therapeutics, Inc. (NASDAQ:CTMX), Dare Bioscience, Inc. (NASDAQ:DARE) appeared first on Stocks Equity .
   Daré Bioscience, Inc. 2022 Q3 - Results - Earnings Call Presentation (NASDAQ:DARE)  2022/11/11 01:47:33 Seeking Alpha
The following slide deck was published by Daré Bioscience, Inc.
   Dare Bioscience GAAP EPS of -$0.08 beats by $0.03 (NASDAQ:DARE)  2022/11/10 14:57:52 Seeking Alpha
Dare Bioscience press release (DARE): Q3 GAAP EPS of -$0.08 beats by $0.03.Cash and cash equivalents: $40.4 million at September 30, 2022, compared to $51.7 million at December…
   Can This Company’s Birth Control Patch Disrupt The Contraceptive Market?  2022/10/26 12:00:00 The North America Newswire
From Evofem Biosciences Inc. ’s (OTCMKTS: EVFM) Phexxi vaginal gel contraceptive to Dare Bioscience Inc. ’s (NASDAQ: DARE) Ovaprene, an investigational hormone-free monthly intravaginal contraceptive, the market is never in short supply of birth control products. While the issue of birth control and abortion can be embroiled in continuous debates and controversies , contraceptives have been known to reduce the rate of unintended pregnancies, the need for unsafe abortions, and HIV transmissions from mothers to newborns. The need is strong - a 2020 report by the World Health Organization (WHO) said that among 1.9 billion reproductive-age women (15 to 49 years) globally in 2019, around 1.1 billion women require family planning and 270 million of those have an unmet need for contraception. Disruptive Contraceptive Patch? The rising number of women with unmet contraceptive drugs and device needs could present unique opportunities for industry players. Agile Therapeutics Inc. ’s (NASDAQ: AGRX) Twirla® (levonorgestrel and ethinyl estradiol) transdermal system could be one innovative product with the potential to disrupt the industry.
   Dare Bioscience Inc. (NASDAQ: DARE) Is A Blank Check For Growth  2022/09/17 13:30:00 Stocks Register
Dare Bioscience Inc. (NASDAQ:DARE) shares, rose in value on Friday, 09/16/22, with the stock price up by 10.00% to the previous day’s close as strong demand from buyers drove the stock to $1.21. Actively observing the price movement in the last trading, the stock closed the session at $1.10, falling within a range of $1.07 … Dare Bioscience Inc. (NASDAQ: DARE) Is A Blank Check For Growth Read More »
   Daré Bioscience (DARE) Investor Presentation - Slideshow (NASDAQ:DARE)  2022/09/13 14:22:00 Seeking Alpha
The following slide deck was published by Daré Bioscience, Inc.
   Dare Bioscience Inc. (DARE): Why Is The Stock Strong?  2022/04/04 18:00:00 Marketing Sentinel
Dare Bioscience Inc. (NASDAQ:DARE) has a beta value of 1.39 and has seen 2.28 million shares traded in the recent trading session. The company, currently valued at $114.11M, closed the recent trade at $1.78 per share which meant it gained $0.07 on the day or 4.39% during that session. The DARE stock price is -41.01% … Dare Bioscience Inc. (DARE): Why Is The Stock Strong? Read More »
   Dare Bioscience Inc. (NASDAQ: DARE) Offers Great Upside  2022/03/31 18:00:00 Stocks Register
Dare Bioscience Inc. (NASDAQ:DARE) shares, rose in value on Thursday, March 31, with the stock price up by 5.78% to the previous day’s close as strong demand from buyers drove the stock to $1.55. Actively observing the price movement in the recent trading, the stock is buoying the session at $1.47, falling within a range … Dare Bioscience Inc. (NASDAQ: DARE) Offers Great Upside Read More »
   Organon Inks Licensing Pact For Daré Bioscience''s Bacterial Vaginosis Treatment  2022/03/31 17:22:05 Benzinga
Organon & Co (NYSE: OGN ) will license global rights to Daré Bioscience Inc''s (NASDAQ: DARE ) Xaciato (clindamycin phosphate vaginal gel, 2%). Xaciato is an FDA-approved medication for treating bacterial vaginosis (BV) in females 12 years of age and older. It has received both Qualified Infectious Disease Product (QIDP) … Full story available on Benzinga.com
   Dare Bioscience GAAP EPS of -$0.63 misses by $0.03 (NASDAQ:DARE)  2022/03/31 13:24:08 Seeking Alpha
Dare Bioscience press release (DARE): FY GAAP EPS of -$0.63 misses by $0.03.Cash and cash equivalents of $51.7 million at December 31, 2021, compared to $4.7 million at December…
   Earnings Scheduled For March 31, 2022  2022/03/31 09:25:32 Benzinga
Companies Reporting Before The Bell • Trevena (NASDAQ: TRVN ) is likely to report earnings for its fourth quarter. • Perma-Fix Envirn Servs (NASDAQ: PESI ) is likely to report earnings for its fourth quarter. • Recruiter.Com Group (NASDAQ: RCRT ) is projected to report quarterly loss at $0.38 per share on revenue of $8.77 million. • SPDR Select Sector Fund - Consumer Discretionary (NYSE: XLY ) is likely to report quarterly loss at $0.01 per share on revenue of $29.80 million. • Welltower (NYSE: WELL ) is projected to report quarterly loss at $0.03 per share on revenue of $112.79 million. • Renalytix (NASDAQ: RNLX ) is projected to report quarterly loss at $0.17 per share on revenue of $500.00 thousand. • 1847 Goedeker (AMEX: GOED ) is projected to report quarterly earnings at $0.05 per share on revenue of $145.00 million. • Celsion (NASDAQ: CLSN ) is likely to report quarterly loss at $0.90 per share on revenue of $120.00 thousand. • Acacia Research (NASDAQ: ACTG ) is likely to report quarterly loss at $0.

calendar